PhosLo Calcium Acetate Phosphate Binder for Kidney Failure

PhosLo contains calcium acetate, a phosphate binder prescribed to reduce elevated blood phosphate in people with end-stage renal disease, often while receiving dialysis. Taken with meals, it binds dietary phosphate in the digestive tract so that less is absorbed. It is not a general calcium supplement and should not be used for ordinary heartburn, routine bone health, or low dietary calcium unless a clinician has specifically prescribed it. PhosLo price depends on the formulation, quantity, coverage, and pharmacy, but it is not a reason to alter a dialysis or phosphate-control plan without clinical guidance.

High phosphate and calcium imbalance in kidney failure require individualized dietary advice, dialysis care, laboratory monitoring, and prescribed medicines. PhosLo does not replace dialysis or renal care. Patients should report symptoms such as new confusion, severe weakness, persistent vomiting, chest symptoms, or major changes in urination promptly to their renal team.

Indications

PhosLo is indicated to control hyperphosphatemia in patients with end-stage renal failure when a prescriber determines calcium acetate is appropriate. Treatment is usually part of a broader plan that may include diet modification, dialysis, laboratory checks, and other kidney-related medicines. People should buy PhosLo only with a valid prescription and through a regulated pharmacy, because phosphate binder selection depends on calcium level, phosphate level, vascular-calcification risk, and other individual factors.

PhosLo should not be used in hypercalcemia. Tell the prescriber about prior high calcium readings, calcium-containing antacids or supplements, heart rhythm problems, kidney treatment, pregnancy, breastfeeding, and all medicines. Review these factors with the renal clinician or pharmacist before starting treatment.

Dosage

Use PhosLo exactly as prescribed and take it with meals, as directed, so it can bind phosphate from food. Capsules commonly contain calcium acetate 667 mg, but the number taken with each meal and any adjustment are individualized according to phosphate, calcium, diet, and tolerability. Patients with a valid prescription can buy PhosLo 667 mg when that capsule strength and meal-time schedule match the written regimen. Do not increase, decrease, crush, or substitute the formulation without prescriber approval.

Early treatment and dose adjustment require frequent serum calcium monitoring; serum phosphorus is also checked periodically. If a dose is missed, do not take extra capsules at the next meal unless the renal team directs it. PhosLo price may vary between pharmacies, but tablets, capsules, and other phosphate binders should not be considered interchangeable without a clinician's instruction. Patients should buy PhosLo only after verifying the product name, dosage form, strength, and directions.

Safety Information

The major risk is hypercalcemia. Mild high calcium can cause constipation, nausea, vomiting, reduced appetite, or increased thirst. More severe hypercalcemia may cause muscle weakness, confusion, delirium, marked fatigue, irregular heartbeat, fainting, stupor, or coma and can require emergency treatment. Long-standing excessive calcium can contribute to vascular or soft-tissue calcification. Seek urgent care for loss of consciousness, severe confusion, a new irregular heartbeat, chest pain, severe weakness, breathing difficulty, or a serious allergic reaction.

Do not take additional calcium supplements or nonprescription calcium-containing antacids unless the renal clinician specifically approves them. Follow prescribed diet and dialysis recommendations. Calcium acetate may be inappropriate with digitalis or digoxin because high calcium can increase arrhythmia risk. Patients should continue scheduled laboratory checks and report nausea, constipation, pruritus, swelling, dizziness, weakness, or other troublesome effects. Cost should never cause skipped doses, use of another person's medicine, or unsupervised changes in phosphate-binder therapy.

Interactions

Calcium acetate can bind other oral medicines in the gut and reduce their absorption. Important examples include tetracycline antibiotics and fluoroquinolone antibiotics; other medicines, including thyroid hormone or bisphosphonates, may also need individualized timing. When a clinically significant interaction is expected, the other oral medicine may need to be taken at least one hour before or at least three hours after calcium acetate, but patients must obtain the timing plan from their pharmacist or prescriber rather than making assumptions.

Provide a complete and updated list of prescription medicines, over-the-counter products, vitamins, and supplements at every appointment. Patients should buy PhosLo through a licensed pharmacy where interaction screening is available. PhosLo price can be discussed with the pharmacy or renal team, but monitoring, dosage, and treatment changes must follow the prescriber's directions.

Medical disclaimer: This content is for informational purposes only and does not replace advice, diagnosis, or treatment from a licensed healthcare professional. It is not a substitute for approved prescribing information or emergency care. Patients should follow their prescriber's directions and consult their healthcare professional about personal medical decisions, symptoms, medicines, monitoring, and treatment changes.